This investigator-initiated study is a factorial, multicentre, randomised controlled trial.
11,140 participants have been recruited and randomised to either a fixed low-dose perindopril-indapamide combination or matching placebo, and to either an intensive modified-release gliclazide-based glucose lowering regimen or standard guidelines-based glucose lowering therapy. Follow-up will be for an average of 5-6 years.

The ADVANCE study design

The primary outcomes will be major macrovascular complications (stroke and heart attack) and major microvascular complications (eye and renal disease).